All In Biotech

Drug Trial Radar · NCT00465517

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as add-on Therapy in Adult Subjects With Epilepsy Consisting of Uncontrolled Partial-onset Seizures.

Last checked: Nov 19, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Feb 2007

Primary completion

Oct 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Marinus PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs). The study will also evaluate the effectiveness of ganaxolone in females with catamenial epilepsy. Catamenial epilepsy refers to a relationship between seizure frequency and a woman's menstrual cycle, where the number of seizures increases around the time of a woman's menstrual cycle.

Conditions

  • Partial Epilepsy
  • Catamenial Epilepsy

Interventions

  • GanaxoloneDrug

    Oral suspension 200-500 mg 3x/day

  • PlaceboOther

    non-active placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10Time frame: Week 1 through Week 10

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Arkansas Epilepsy Program

    Little Rock, Arkansas

  • University of Southern California Adult Comprehensive Epilepsy Center

    Los Angeles, California

  • University of California-Davis

    Sacramento, California

  • Anchutz Outpatient Pavillion Neurosciences Clinic/ University of Colorado Hospital

    Aurora, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • University of Florida McKnight Brain Institute

    Gainesville, Florida

  • Intercoastal Medicine

    Sarasota, Florida

  • Emory HealthCare

    Atlanta, Georgia

  • Southern Illinois University Medical Center

    Springfield, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kentucky, Dept. of Neurology

    Lexington, Kentucky

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • 2799 West Grand blvd. CFP 071

    Detroit, Michigan

  • Minnesota Epilepsy Group, PA

    Saint Paul, Minnesota

  • Comprehensive Epilepsy Care Center for Children and Adults

    Chesterfield, Missouri

  • Overlook Hospital and Hackensack Medical Center

    Hackensack, New Jersey

  • Neurosciences Institute at Albany Medical Center

    Albany, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Ohio State University Medical Center

    Columbus, Ohio

  • Riddle Health Care Center for Neuroscience

    Media, Pennsylvania

  • Drexel University / Hahneman Hospital

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Ctr

    Nashville, Tennessee

  • Neurological Clinic of Texas, P.A.

    Dallas, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.